Suppr超能文献

在 cords 内注射止血时给予肾上腺素以改变生命体征:心肺骤停时气管内给予肾上腺素的假设性设计的观察性研究。

Changes in vital signs during adrenaline administration for hemostasis in intracordal injection: an observational study with a hypothetical design of endotracheal adrenaline administration in cardiopulmonary arrest.

机构信息

Tokyo Voice Center, International University of Health and Welfare, 8-5-35 Akasaka, Minato-ku, Tokyo, 107-0052, Japan.

出版信息

J Cardiothorac Surg. 2023 Oct 6;18(1):271. doi: 10.1186/s13019-023-02376-1.

Abstract

BACKGROUND

The background is that intravenous adrenaline administration is recommended for advanced cardiovascular life support in adults and endotracheal administration is given low priority. The reason is that the optimal dose of adrenaline in endotracheal administration is unknown, and it is ethically difficult to design studies of endotracheal adrenaline administration with non-cardiopulmonary arrest. We otolaryngologists think so because we administered adrenaline to the vocal folds for hemostasis after intracordal injection under local anesthesia, but have had few cases of vital changes. We hypothesized that examining vital signs before and after adrenaline administration for hemostasis would help determine the optimal dose of endotracheal adrenaline.

METHODS

We retrospectively examined the medical records of 79 patients who visited our hospital from January 2018 to December 2020 and received adrenaline in the vocal folds and trachea for hemostasis by intracordal injection under local anesthesia to investigate changes in heart rate and systolic blood pressure before and after the injection.

RESULTS

The mean heart rates before and after injection were 83.96 ± 18.51 (standard deviation) beats per minute (bpm) and 81.50 ± 15.38 (standard deviation) bpm, respectively. The mean systolic blood pressure before and after the injection were 138.13 ± 25.33 (standard deviation) mmHg and 135.72 ± 22.19 (standard deviation) mmHg, respectively. Heart rate and systolic blood pressure had P-values of 0.136, and 0.450, respectively, indicating no significant differences.

CONCLUSIONS

Although this study was an observational, changes in vital signs were investigated assuming endotracheal adrenaline administration. The current recommended dose of adrenaline in endotracheal administration with cardiopulmonary arrest may not be effective. In some cases of cardiopulmonary arrest, intravenous and intraosseous routes of adrenaline administration may be difficult and the opportunity for resuscitation may be missed. Therefore, it is desirable to have many options for adrenaline administration. Therefore, if the optimal dose and efficacy of endotracheal adrenaline administration can be clarified, early adrenaline administration will be possible, which will improve return of spontaneous circulation (ROSC) and survival discharge rates.

摘要

背景

背景是,在成人的高级心血管生命支持中推荐静脉内给予肾上腺素,而气管内给予肾上腺素则优先级较低。原因是气管内给予肾上腺素的最佳剂量未知,并且出于伦理原因,很难设计非心肺骤停患者的气管内给予肾上腺素的研究。我们耳鼻喉科医生认为,因为我们在局部麻醉下经声带内注射后,将肾上腺素给予声带以止血,但很少有生命体征变化的病例。我们假设在止血时检查肾上腺素给药前后的生命体征,将有助于确定气管内给予肾上腺素的最佳剂量。

方法

我们回顾性地检查了 2018 年 1 月至 2020 年 12 月期间来我院就诊并接受局部麻醉下声带内注射肾上腺素止血的 79 例患者的病历,以调查注射前后心率和收缩压的变化。

结果

注射前和注射后的平均心率分别为 83.96±18.51(标准差)次/分钟(bpm)和 81.50±15.38(标准差)bpm。注射前和注射后的平均收缩压分别为 138.13±25.33(标准差)mmHg 和 135.72±22.19(标准差)mmHg。心率和收缩压的 P 值分别为 0.136 和 0.450,表明差异无统计学意义。

结论

尽管本研究是一项观察性研究,但假设进行了气管内肾上腺素给药,调查了生命体征的变化。目前在心肺骤停患者中气管内给予肾上腺素的推荐剂量可能无效。在某些心肺骤停的情况下,静脉内和骨髓内给予肾上腺素可能会很困难,从而错失复苏机会。因此,希望有更多的肾上腺素给药选择。因此,如果能明确气管内给予肾上腺素的最佳剂量和疗效,就可以早期给予肾上腺素,从而提高自主循环恢复(ROSC)和生存出院率。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验